11 master-"https:" "https:" "https:" "https:" positions at King's College London in United Kingdom
Sort by
Refine Your Search
-
Listed
-
Category
-
Field
-
mandatory secondments (3–6 months) with partner institutions, and participate in network-wide training events. Note: The applicant must not have resided or carried out their main activity (work/studies) in
-
the lifespan. Note: The applicant must not have resided or carried out their main activity (work/studies) in the United Kingdom for more than 12 months in the 36 months immediately before the recruitment date
-
& Sciences (SCMMS) provides an outstanding multi-disciplinary environment for the pursuit of cutting-edge cardiovascular and metabolic research (https://www.kcl.ac.uk/scms ). We study the fundamental molecular
-
in Europe devoted to the study and prevention of mental illness and brain disease. The IoPPN pioneers research into new and improved ways of understanding and treating mental ill health (http
-
research into new and improved ways of understanding and treating mental ill health ( http://www.kcl.ac.uk/ioppn/ ). The research role is based in the Psychology Department, one of the world’s largest
-
the Heat and Fire Lab (https://heatandfire.github.io/ ) in the Department of Engineering at King’s College London. About the role We are looking to appoint a full-time (1.0 FTE) Research Associate to work
-
stage. Find out more here - https://www.kcl.ac.uk/about About the role: As King’s College London approaches a landmark period—launching a new Philanthropy and Engagement Campaign in 2027 and celebrating
-
& Metabolic Medicine & Sciences (SCMMS) provides an outstanding multi-disciplinary environment for the pursuit of cutting-edge cardiovascular and metabolic research (https://www.kcl.ac.uk/scmms ). We study the
-
Engineering & Imaging Sciences (BMEIS) and the Royal Brompton Hospital’s Imaging Department in Chelsea. The School of BMEIS (https://www.kcl.ac.uk/bmeis ) is committed to improving the way we deliver healthcare
-
. This role will oversee a Phase 2/3 multi-arm, multi-stage (MAMS) trial evaluating the safety and efficacy of repurposed biosimilars and biologics in adults with epidermolysis bullosa (EB). https